A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Small Lymphocytic Lymphoma Clinical Trial

Official title:

A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05272813
• Other study ID #: 2020-001-CN
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 28, 2022
• Est. completion date: September 2025

Study information

• Verified date: October 2023
• Source: MingSight Pharmaceuticals, Inc
• Contact: Ling Yang
• Phone: +8613421382136
• Email: yangling[@]relin.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: September 2025
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older, male or female.
• Diagnosis of CLL/SLL per IWCLL2018 criteria.
• Patients with relapsed or refractory CLL/SLL who have failed at least 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy), are indicated for treatment per IWCLL2018.
• Measurable lesions detected by contrast-enhanced computed tomography (CT): at least one lymph node with a maximum axis of more than 1.5 cm and one measurable vertical dimension.
• WHO/ECOG performance status of 0 to 2.
• Patients with an estimated survival of more than 3 months.

Exclusion Criteria:

• Biopsy-proven and pathologically confirmed current or past transformation to Richter's syndrome.
• Patients with active and uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura.
• Patients who have received any of the following treatments within 14 days prior to the

first dose:

• Major surgery;
• Glucocorticoids (at a dose equal to or greater than 20 mg/day prednisone or equivalent), unless used by inhalation, topical or intraarticular route, or unless necessary for premedication before and after iodinated contrast dye. After discussion with the Sponsor, steroid therapy at high doses for an extended period

may be allowed under the following circumstances:

1. Treatment of autoimmune hemolysis or autoimmune thrombocytopenia associated with CLL/SLL;

2. Short-term (within 14 days) use to treat inactive infections of diseases unrelated to CLL/SLL (e.g. arthritis, asthma), which results in acute exacerbation, including steroid dose modifications required for adrenal insufficiency;

• Cytotoxic chemotherapy or biologic therapy, excepting BCR pathway kinase inhibitors for which a washout of 24 hours prior to the first dose is required.
• Toxicity from prior anti-tumor therapy (chemotherapy, radiotherapy, or biotherapy) did not restore to = Grade 1 (except for alopecia); atrial fibrillation from prior treatment with BTK inhibitors did not restore to = Grade 2.
• Central nervous system (CNS) leukemia or lymphoma, including a history of asymptomatic, previously treated CNS disease.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Lymphocytic Leukemia
• Lymphoma
• Small Lymphocytic Lymphoma

Intervention

Drug:
• MS-553
MS-553

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing	Xicheng District

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose limiting toxicities		28 days
Secondary	Incidence and severity of adverse events		Assessed throughout the study from the time of first dose of study drug until 30 days after the patient's last dose of study drug or until the event has resolved, stabilized, or an outcome reached, whichever comes first regardless of timing of EoT visit
Secondary	Overall response rate		up to 24 months
Secondary	Time to tumor response		During intervention
Secondary	Disease control rate		During intervention
Secondary	Progression free survival		During intervention
Secondary	Overall survival		During intervention
Secondary	Assessment of minimal residual disease		During intervention